News and Trends 17 Mar 2023
Likang gets trial ok for China’s first personalized cancer vaccine
Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 injection. This is the first personalized neoantigen vaccine and…